Skip to Content

Davabazaar in India Vision and Objective

Davabazaar in India website is a Pharma Trade Portal which caters to end patients and their relatives, chemist and medical stores, pharmacist and other pharma workers, doctors and nursing homes, hospitals and medical institutions, pharmaceutical manufactures and allied service providers, trade and manufactures associations.

For patients and relatives we have Ask-the-Doctor medical forums, health blogs, chats and patient health communities.

Drug Index Software

Very soon the drug index software will be available for download. This software and all further upgrades are available free of cost to chemist and medical doctors. Please register and get yourself verified. Pharmaceutical companies who wish to add their information should also register and get verified.

Correspondent's picture

Pharma Overview

Pharmaceutical OverviewLast Updated: April 2009

Sector structure/Market size


The Indian pharmaceutical industry is driving product development and breaking new grounds in medicine research worldwide.


The Indian domestic pharmaceutical market is estimated to be US$ 10.76 billion in 2008 and is expected to grow at a high compound annual growth rate (CAGR) of 9.9 per cent till 2010 and thereafter at a CAGR of 9.5 per cent till 2015.

Correspondent's picture

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.

Correspondent's picture

Novel Drug for Chronic Management of Hyperuricemia in Gout Patients

Teijin Pharma Limited announced the European launch of TMX-67 (febuxostat), a novel drug discovered by Teijin Pharma for the treatment of hyperuricemia in patients with gout. Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r).

Correspondent's picture

Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

Correspondent's picture

FDA Panel Recommends InterMune Drug Approval for Lung Disease

An FDA advisory panel voted 9–3 to recommend approval of InterMune’s Esbriet to slow the decline in lung function in patients with idiopathic
pulmonary fibrosis (IPF), despite agency staff concerns about proof of efficacy.

Correspondent's picture

FDA’s Hamburg Testifies on Patient Protection, User Fees

FDA Commissioner Margaret Hamburg yesterday told a Senate appropriations subcommittee that an increase of $101 million in funding — $51 million
of which would come from two new user fees — would be needed to finance a critical patient-safety measure.

Correspondent's picture

Full Issue

View the entire issue.

Correspondent's picture

OxyContin Patent Allegations Dismissed Against Purdue

Six plaintiffs have dropped accusations that Purdue Pharma prevented generic competition for its painkiller OxyContin through misrepresentations to
the PTO and sham patent litigation.

Syndicate content